Search company, investor...


Founded Year



Reverse Merger | IPO

Total Raised


About Replidyne

Replidyne is a drug discovery and development firm focused on a new class of antibiotics

Headquarters Location

1450 Infinite Drive

Louisville, Colorado, 80027,

United States


Missing: Replidyne's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Replidyne's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Replidyne

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Replidyne is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

Replidyne Patents

Replidyne has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Antibiotics, Diabetes, Carboxylic acids, Units of information, Liberal democracies


Application Date


Grant Date



Related Topics

Antibiotics, Diabetes, Carboxylic acids, Units of information, Liberal democracies



Latest Replidyne News

SRS Expands into Life Sciences

Apr 21, 2011

SRS Expands into Life Sciences April 21, 2011 By PEHub Administrator Shareholder Representative Services, a four-year-old, San Francisco-based service provider that represents shareholders in the post-closing period after a company has been acquired, has expanded into life sciences. Leading the practices is Don Morrissey, who in the past has served as senior vice president of corporate development at Replidyne and VP of legal affairs and business development at Caliper Life Sciences. Morrissey was also previously an attorney at Cooley LLP. PRESS RELEASE: SAN FRANCISCO, CA (April 21, 2011) – SRS | Shareholder Representative Services today announced that industry veteran Don Morrissey has joined the company to lead its life sciences practice SRS’ life sciences practice focuses on maximizing returns for sellers in their M&A exits. In the majority of these deals, a significant portion of the total consideration — sometimes hundreds of millions of dollars — is subject to the achievement of specific milestones, including regulatory approval and sales objectives. For this reason, overall deal value is highly influenced by post-closing management and the ability to negotiate disputes. Furthermore, earnout periods can last years, requiring the attention and expertise of the shareholder representative long after the deal closes. SRS has served as shareholder representative on numerous life sciences deals, including the recent acquisitions of Plexxikon by Daiichi Sankyo and Calistoga Pharmaceuticals by Gilead Sciences. Selling shareholders recognize that SRS offers the institutional knowledge, relationship management, and expertise necessary to ensure that their interests are fully represented after closing. “The post-closing period after the sale of a life sciences company is often complex, because determining whether progress toward the achievement of milestones is adequate can be subject to interpretation,”  said Paul Koenig, Managing Director of SRS. “Questions surrounding whether milestones are on track and if not, why not, can lead to disputes and sometimes even litigation. Engaging an expert to manage this process is critical because there is so much at stake. ” Don Morrissey has joined the firm as an executive director and head of the life sciences practice. Morrissey brings over 15 years of leadership experience in the life sciences sector, including serving as SVP of Corporate Development and General Counsel at Replidyne and VP of Legal Affairs and Business Development at Caliper Life Sciences. He began his career as an attorney at Cooley LLP. “Life science company executives and investors have long known how important it is to actively manage their alliances with larger partners to keep development projects prioritized and progressing,”  said Morrissey. “Now, the most promising projects often continue under structured acquisition arrangements rather than corporate partnering deals. But the imperative to engage the partner, quarter after quarter, year after year, doesn’t go away just because the management team does. That’s where SRS can help.” About SRS SRS | Shareholder Representative Services is the leading global expert in professionally managing the post-closing process to safeguard the selling shareholders’ interests in private company M&A transactions. As the shareholder representative, SRS manages all post-closing matters, including working capital and other purchase price adjustments, tax reviews, the handling of claims, disputes and litigation, communications with acquirers and selling shareholders, and management and distribution of escrow and expense funds. On deals valued in aggregate in excess of $16 billion, SRS has represented more than 400 venture capital and private equity firms and over 19,000 shareholders in 44 countries. No one has as much knowledge and experience in serving as a shareholder representative and navigating the issues that arise post-closing than SRS. For more information, visit . © 2015 Buyouts Insider / Argosy Group LLC

Replidyne Frequently Asked Questions (FAQ)

  • When was Replidyne founded?

    Replidyne was founded in 2000.

  • Where is Replidyne's headquarters?

    Replidyne's headquarters is located at 1450 Infinite Drive, Louisville.

  • What is Replidyne's latest funding round?

    Replidyne's latest funding round is Reverse Merger.

  • How much did Replidyne raise?

    Replidyne raised a total of $121.5M.

  • Who are the investors of Replidyne?

    Investors of Replidyne include Cardiovascular Systems, Morgenthaler Ventures, Sequel Venture Partners, Aisling Capital, Perseus and 10 more.

  • Who are Replidyne's competitors?

    Competitors of Replidyne include Carmot Therapeutics, 2cureX, Melinta Therapeutics, BrightPath Biotherapeutics, CeNeRx BioPharma and 11 more.

Compare Replidyne to Competitors

Graffinity Pharmaceuticals AG

Graffinity is a partner for fragment based drug discovery and lead development of small molecule pharmaceuticals


Abmart aims to develop highly scaled production of antibodies for the drug discovery applications

De Novo Pharmaceuticals

De Novo Pharmaceuticals Ltd is a computationally-based drug discovery company focused on small molecule therapeutics. De Novo develops a suite of structure-generating programs called SkelGen. The core algorithm generates new molecular structures by the random assembly of small molecular fragments in situ. Ninety-percent of the structures produced by SkelGen is chemically tractable.

Actimis Pharmaceuticals

Actimis Pharmaceuticals is a bio-pharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders.

IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.


Combichem offers drug discovery and development services

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.